Prevalence of Thyroid Dysfunction and Anti-thyroid Antibodies in Infertile Women

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03964779

Enrollment

120

Registered

2019-05-28

Start date

2019-05-31

Completion date

2020-01-31

Last updated

2019-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Brief summary

The study population will be divided into three groups: * Group (A) consisting of 40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility, * Group (B) consisting of 40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility, and * Group (C) consisting of 40 women with exclusive male factor of infertility and will be used as a control group. . All women will be subjected to: * Informed consent * Full history taking, including age, duration of infertility and whether primary or secondary * General and pelvix examination * Trans-vaginal ultrasonography * Determination of hormonal profile (FSH, LH, Estradiol, Prolactin) * Determination of ovulatory status * Determination of of tubal patency * Determination of presence of male factor * Determination of TSH and antithyroid antibodies (antithyroglobulin and antithyroid peroxidase) blood levels

Detailed description

The study population will be divided into three groups: * Group (A) consisting of 40 infertile women with either unexplained or anovulatory infertility with/without associated male factor of infertility, * Group (B) consisting of 40 infertile women with tubal (mechanical) factor of infertility with/without associated male factor of infertility, and * Group (C) consisting of 40 women with exclusive male factor of infertility and will be used as a control group. . All women will be subjected to: * Informed consent * Full history taking, including age, duration of infertility and whether primary or secondary * General and pelvix examination * Trans-vaginal ultrasonography * Determination of hormonal profile (FSH, LH, Estradiol, Prolactin) * Determination of ovulatory status (by previous documented history of induction of ovulation OR previous ultrasonography OR previous estimation midluteal serum progesterone, etc …) * Determination of of tubal patency (by previous hysterosalpingiography or laparoscopy) * Determination of presence of male factor (by seminal fluid analysis) * Determination of TSH and antithyroid antibodies (antithyroglobulin and antithyroid peroxidase) blood levels

Interventions

DIAGNOSTIC_TESTHormonal assay

Measurement of Thyroid stimulating hormone

DIAGNOSTIC_TESTAntibody assay

antithyroglobulin and antithyroid peroxidase

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Inclusion criteria

* \- Age: 18 - 38 years * Infertile women whether due to functional, anatomical, male factors OR unexplained OR combined factors

Exclusion criteria

* \- Age: below 18 and above 38 years * Patients with autoimmune diseases (such as lupus and rheumatoid arthritis) * Acute illness that require hospitalization * Patients on the following medications: steroids, dopamine, iodine, amiodarone, lithium, donperidone, thyroid hormone, and phenytoin. * Patients who work at night.

Design outcomes

Primary

Measure	Time frame	Description
prevalence of thyroid dysfunction among infertile women	through study completion, an average of 6 months	prevalence of thyroid dysfunction (clinical or subclinical, hypothyroidism or hyperthyroidism) among infertile women

Countries

Egypt

Contacts

Primary ContactAhmed Maged

prof.ahmedmaged@gmail.com+201005227404

Backup ContactAhmed wali

ahmed.wali@kasralainy.edu.eg+201001735088

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026